CN112569364A - 一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒及其制备方法和应用 - Google Patents
一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒及其制备方法和应用 Download PDFInfo
- Publication number
- CN112569364A CN112569364A CN202011496736.4A CN202011496736A CN112569364A CN 112569364 A CN112569364 A CN 112569364A CN 202011496736 A CN202011496736 A CN 202011496736A CN 112569364 A CN112569364 A CN 112569364A
- Authority
- CN
- China
- Prior art keywords
- glucan
- iron oxide
- beta
- superparamagnetic nano
- coupled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 80
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title claims abstract description 79
- 239000002245 particle Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 31
- 239000002105 nanoparticle Substances 0.000 claims abstract description 18
- 201000001441 melanoma Diseases 0.000 claims abstract description 12
- 238000005859 coupling reaction Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 13
- 239000012154 double-distilled water Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 235000019441 ethanol Nutrition 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000009977 dual effect Effects 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 24
- 210000002540 macrophage Anatomy 0.000 abstract description 14
- 230000010287 polarization Effects 0.000 abstract description 10
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 8
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000008878 coupling Effects 0.000 abstract description 3
- 238000010168 coupling process Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- 230000002147 killing effect Effects 0.000 abstract description 2
- 241000399119 Spio Species 0.000 abstract 2
- 235000013980 iron oxide Nutrition 0.000 description 23
- 239000000243 solution Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000009562 Forkhead Box Protein O3 Human genes 0.000 description 1
- 108010009307 Forkhead Box Protein O3 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108050004365 Transcription factor Maf Proteins 0.000 description 1
- 102100039189 Transcription factor Maf Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000037967 hot tumor Diseases 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种β‑葡聚糖偶联超顺磁纳米氧化铁颗粒及其制备方法和应用。一种β‑葡聚糖偶联超顺磁纳米氧化铁颗粒,为表面偶联β‑葡聚糖的超顺磁纳米氧化铁颗粒。本发明基于SPIO纳米颗粒本身特性,将β‑葡聚糖和SPIO偶联形成新纳米颗粒,既可以通过磁共振成像技术对肿瘤进行诊断,又可以增强到达肿瘤部位的纳米颗粒对肿瘤细胞的杀伤作用,同时,到达其他部位的纳米颗粒对健康细胞没有显著的细胞毒性。本发明通过实验发现BSNPs能够活化巨噬细胞、促进肿瘤相关巨噬细胞向M1型极化,并缓解小鼠黑色素瘤,具有较大治疗黑色素瘤的潜力。
Description
技术领域
本发明属于生物医药领域,涉及一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒及其制备方法和应用。
背景技术
肿瘤是人类的头号杀手,被称为万疾之王,尽管近十年来新增了很多针对肿瘤治疗的方案,但并非所有的患者都能适用,即使是当下热门的肿瘤免疫疗法,也有治疗时间长、费用昂贵、不良反应严重等缺点。因此,迫切需要探寻更安全、有效的治疗方法和新的辅助治疗策略。
已有文献表明β-葡聚糖具有良好的抗肿瘤活性,口服β-葡聚糖能够缓解小鼠肉瘤,包括缩小肿瘤体积、降低肿瘤重量、促进肿瘤细胞凋亡等[1]。口服β-葡聚糖能够缓解大鼠乳腺癌,通过活化FOXO3通路促进肿瘤细胞凋亡[2]。此外,也有文献表明β-葡聚糖通过下调原癌基因c-Maf影响巨噬细胞分化功能基因CSF1R的表达,从而影响巨噬细胞极化[3];腹腔注射β-葡聚糖通过促进肿瘤相关巨噬细胞向M1型极化从而缓解小鼠结肠癌[4]。尽管口服、腹腔注射、静脉注射都是β-葡聚糖常见的给药方式,但是药代动力学研究表明不同的给药方式会影响β-葡聚糖在不同组织器官的浓度,从而影响其生物学功能。那么,如何安全、有效的利用β-葡聚糖显得尤为重要。
磁共振成像技术是临床上常用的疾病诊断方法,其基本原理在于,使用特定频率的射频脉冲激发氢原子核,使其从基态变为激发态,停止射频脉冲后,激发态的氢原子核发生弛豫释放能量恢复基态,通过磁场辅助定位人体内的氢原子核,通过仪器检测弛豫状态并采集弛豫时间,经过特殊算法处理重现人体内部影像。根据影像中明暗比例、形状等信号可反映脑、肝、软骨、肌肉、韧带等等各个组织脏器的生理结构或病理变化,而造影剂可以通过对氢原子核弛豫时间的改变,可以提高核磁共振成像的对比度,使得图像明暗变化更为清晰,通过调整算法使肿瘤组织与健康人体组织的图像纹理差异更大,从而有利于发现体积较小、与正常组织脏器解剖结构完全不同的肿瘤因此,作为磁共振成像造影剂的物质并不一定具备肿瘤靶向性.
超顺磁纳米氧化铁(Superparamagnetic iron oxides,SPIO)是粒径在纳米级别的磁性纳米颗粒,在20世纪80年代SPIO就已经作为造影剂出现[5,6]。但SPIO作为显影剂并未见其具有肿瘤靶向性的相关报道。SPIO作为造影剂,其造影原理在于:注射进入人体后,可以快速分布到全身各组织,在核磁共振仪发射具有空间位置依赖性的梯度磁场并通过计算机软件经过特殊算法将采集的信号转化为影像,以此区别正常组织和肿瘤。SPIO不能特异性富集到肿瘤部位,SPIO作为造影剂只有结合核磁共振仪才能发挥辅助诊断作用,不经过特殊处理(包括尺寸、形状、修饰等)不具备抗肿瘤作用。
尽管合成SPIO时常使用羧甲基聚葡萄糖成壳包裹铁核,但羧甲基聚葡萄糖并不具有良好的生物学活性,我们前期的实验结果也显示单独SPIO没有抗肿瘤功能[7]。具有良好生物学活性的β-葡聚糖由于其分子构象不适合成壳因而不能直接用于合成纳米氧化铁。本发明还发现简单混合使用β-葡聚糖和SPIO疗效也不理想。
[1]Mo L,Chen Y,Li W,et al.Anti-tumor effects of(1→3)-β-d-glucan fromSaccharomyces cerevisiae in S180 tumor-bearing mice[J].International Journalof Biological Macromolecules,2017,95:385-392.
[2]Geraldelli D,Ribeiro M C,Medeiros T C,et al.Botryosphaeran,a(1→3)(1→6)-β-D-glucan,reduces tumor development and cachexia syndrome in obesemale rats by increasing insulin sensitivity and FOXO3a activity[J].International Journal of Biological Macromolecules,2020,165:985-994.
[3]Garcia J R C,Rodriguez P C.c-Maf:a bad influence in the educationof macrophages[J].J Clin Invest,2020,130(4):1629-1631.
[4]Cheng H,Sun L,Shen D,et al.Beta-1,6glucan converts tumor-associated macrophages into an M1-like phenotype[J].Carbohydr Polym.2020,247:116715.
[5]Dias M H M,Lauterbur P C.Ferromagnetic particles as contrastagents for magnetic resonance imaging of liver and spleen[J].MagneticResonance in Medicine,1986,3(2):328-330.
[6]Zheng B,Vazin T,Goodwill P W,et al.Magnetic Particle Imagingtracks the long-term fate of in vivo neural cell implants with high imagecontrast[J].Scientific Reports,2015,5:14055.
[7]Zhao J,Zhang Z,Xue Y,et al.Anti-tumor macrophages activated byferumoxytol combined or surface-functionalized with the TLR3 agonist poly(I:C)promote melanoma regression[J].Theranostics,2018,8(22):6307-6321.
发明内容
本发明的目的是针对现有技术的上述不足,提供一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒。
本发明的另一目的是提供该β-葡聚糖偶联超顺磁纳米氧化铁颗粒的制备方法。
本发明的又一目的是提供该β-葡聚糖偶联超顺磁纳米氧化铁颗粒的应用。
本发明的目的可通过以下技术方案实现:
一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒,为表面偶联β-葡聚糖的超顺磁纳米氧化铁颗粒。
作为本发明的一种优选,所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒是β-葡聚糖和超顺磁纳米氧化铁壳上的羧基在EDC的催化下耦合反应制得;其中β-葡聚糖和超顺磁纳米氧化铁的质量比为1-3:5。
本发明所述的β-葡聚糖的来源可为燕麦、酵母、解纤维热酸菌等,SPIO可为商品或自制纳米材料,只要外壳为羧甲基聚葡萄糖即可
作为本发明的进一步优选,所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒通过以下方法制备得到:
1)取超顺磁纳米氧化铁溶于双蒸水中,加EDC,混合均匀,加β-葡聚糖,容器封口后25-28℃搅拌14-20小时,搅拌速度为600-800rpm;
2)将步骤(1)所得溶液浓缩后加无水乙醇混合均匀,静置产生棕色沉淀;
3)分离出沉淀,于25-37℃静置10-20分钟以挥干剩余的乙醇;
4)用水重悬,配置需要浓度的溶液,超声处理15-30min以充分分散纳米颗粒,即得到所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒;
或者,其中的步骤2)和3)替换为:
2)将步骤1)所得溶液使用100000kDa分子量透析袋在100倍体积的双蒸水中透析2天,期间至少更换4次透析液;
3)取透析袋中的液体冻干成粉。
作为本发明的更进一步优选,所述的β-葡聚糖的浓度为0.2-0.6mg/mL,超顺磁纳米氧化铁的浓度为1mg/mL,EDC的浓度为1-1.5mg/mL。
本发明所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒的制备方法,利用EDC作为催化剂催化β-葡聚糖与超顺磁纳米氧化铁壳上的羧基反应从而将β-葡聚糖偶联到超顺磁纳米氧化铁壳上;其中β-葡聚糖和超顺磁纳米氧化铁的质量比为1-3:5。
作为本发明的一种优选,所述的制备方法包含以下步骤:
1)取超顺磁纳米氧化铁溶于双蒸水中,加EDC,混合均匀,加β-葡聚糖,容器封口后25-28℃搅拌14-20小时,搅拌速度为600-800rpm;
2)将步骤(1)所得溶液浓缩后加无水乙醇混合均匀,静置产生棕色沉淀;
3)分离出沉淀,于25-37℃静置10-20分钟以挥干剩余的乙醇;
4)用水重悬,配置需要浓度的溶液,超声处理15-30min以充分分散纳米颗粒,即得到所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒;
或者,其中的步骤2)和3)替换为:
2)将步骤1)所得溶液使用100000kDa分子量透析袋在100倍体积的双蒸水中透析2天,期间至少更换4次透析液;
3)取透析袋中的液体冻干成粉。
作为本发明的进一步优选,所述的β-葡聚糖的浓度为0.2-0.6mg/mL,超顺磁纳米氧化铁的浓度为1mg/mL,EDC的浓度为1-1.5mg/mL。
本发明所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒在制备抗肿瘤药物中的应用,优选在制备具备肿瘤诊断和治疗双重功能的药物中的应用;进一步优选在制备具备黑色素瘤诊断和治疗双重功能的药物中的应用。
一种药物组合物,包含本发明所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒和药学上允许的载体。
有益效果:
本发明基于SPIO纳米颗粒本身特性,将β-葡聚糖和SPIO偶联形成新纳米颗粒,既可以通过磁共振成像技术对肿瘤进行诊断,又可以增强到达肿瘤部位的纳米颗粒对肿瘤细胞的杀伤作用,同时,到达其他部位的纳米颗粒对健康细胞没有显著的细胞毒性。本发明通过实验发现BSNPs能够活化巨噬细胞、促进肿瘤相关巨噬细胞向M1型极化,并缓解小鼠黑色素瘤,具有较大治疗黑色素瘤的潜力。
附图说明
图1.BSNPs表征
A为BSNPs水合粒径分布,B为BSNPs的Zeta电位,C为使用电子显微镜拍摄的BSNPs颗粒形态
图2.小鼠磁共振成像结果
图3.BSNPs对小鼠黑色素瘤的作用
A为生存曲线,B为肿瘤体积变化情况,C为小鼠体重变化情况,D为小鼠肿瘤重量变化情况
图4流式细胞术检测分析巨噬细胞上CD68(M1型巨噬细胞表面标志)和CD206(M2型巨噬细胞表面标志)的荧光强度
A为M1型巨噬细胞表面标志极化情况,B为M2型巨噬细胞表面标志极化情况
具体实施方式
实施例1
1.1原料:
β-葡聚糖(CAS:9041-22-9)、超顺磁纳米氧化铁(Superparamagnetic ironoxides,SPIO)、1-乙基-3-(3-二甲氨基)-碳二亚胺(EDC)。
1.2合成步骤:
1)取20mg SPIO溶于含有20mL双蒸水的玻璃锥形瓶中,加23mg EDC,室温搅拌5-10分钟,加4或8mgβ-葡聚糖,容器封口后室温搅拌过夜(14-20小时),搅拌速度为800rpm;
2)将步骤(1)所得溶液浓缩至1mL左右;
3)将步骤(2)所得浓缩液加4倍体积无水乙醇混合均匀,此时溶液应为棕色混悬液,静置有棕色沉淀;
4)以12000rpm离心15分钟,离心结束时应有紧实的沉淀,上清无色透明;
5)弃上清,于室温或37℃静置10-20分钟以挥干剩余的乙醇;
6)用水重悬,配置需要浓度的溶液,超声处理20min以充分分散纳米颗粒,即得到β-葡聚糖偶联SPIO纳米颗粒(β-glucan-SPIO nano-particles,BSNPs)。
1.3BSNPs表征:
1.3.1纳米颗粒水合粒径检测:
取适量BSNPs溶于双蒸水中,配置成1mg/mL的溶液,置于动态光散射粒径分析仪配套样品槽中,上机检测,BSNPs平均水合粒径约为29nm。
1.3.2纳米颗粒Zeta电位检测:
取适量BSNPs溶于双蒸水中,配置成1mg/mL的溶液,置于Zeta纳米粒度电位仪配套样品槽中,插入电极,选择Zeta电位检测程序后上机检测,BSNPs平均Zeta电位为-31至-35mV。
1.3.3电子显微镜拍摄:
取适量BSNPs溶于双蒸水中,配置成20mg/mL的溶液,送样至南京大学现代分析中心检测,拍摄纳米颗粒形态照片。
使用动态光散射粒径分析仪分析BSNPs纳米材料粒径及Zeta电位,并使用电子显微镜拍摄BSNPs颗粒形态。结果显示BSNPs水合粒径约为29nm(图1A),比SPIO水合粒径稍大一些,Zeta电位约为-34mV(图1B),形态为球形(图1C)。
实施例2BSNPs生物学活性检测:
2.1细胞培养:
选取小鼠黑色素瘤细胞B16F10(购自中国科学院细胞库)细胞,将细胞培养于含10%胎牛血清和1%双抗(青霉素和链霉素)的DMEM培养基(均购自上海基峰生物科技有限公司)中,37℃,5%CO2培养。待细胞长至80-90%汇合度时传代,用胰蛋白酶消化液室温消化半分钟后用培养基反复吹打,制备成细胞悬液,取适量铺到相应的培养皿进行传代,或铺至细胞培养板进行后续实验,每天用倒置显微镜观察细胞形态及其生长情况。
2.2动物模型验证BSNPs对黑色素瘤的治疗作用:
1)取2.1中制备得到的吹打均匀的小鼠黑色素瘤细胞B16F10的细胞悬液50μL,移至Countstar细胞计数板中,使用Countstar细胞计数仪进行细胞计数;
2)取足够量的细胞置于50mL离心管中,使用磷酸盐缓冲液(PBS,pH=7.4)补至50mL,1500rpm离心5min;
3)弃上清,使用2mL PBS重悬细胞,并再次加PBS补至50mL,1500rpm离心5min;
4)弃上清,根据步骤(1)所得细胞数,加适量PBS重悬细胞,配置成终浓度为2.5×106个/mL的细胞悬液;
5)每只鼠取200μL步骤(4)中所得细胞悬液,即5×105个B16F10细胞,经皮下注射构建小鼠黑色素瘤模型;
6)注射肿瘤细胞14天后,肿瘤体积约为100mm3时,隔日尾静脉注射生理盐水(Control)200μL/只、β-葡聚糖(BG)40μg/只、β-葡聚糖和SPIO的混合液(BG+SPIO,β-葡聚糖40μg/只与SPIO 200μg/只)或者BSNPs(实验采用β-葡聚糖和SPIO比例为1:5制备而得的BSNPs)200μg/只,隔日注射一次,并记录小鼠体重、肿瘤体积变化;
7)注射肿瘤16天后,注射BSNPs 24h时麻醉小鼠,于磁共振成像仪下进行活体检测,拍摄肿瘤部位成像照片;
8)注射肿瘤细胞26天时,称重后处死小鼠,取肿瘤组织称重。
小鼠磁共振成像结果显示,BSNPs组和BG+SPIO组小鼠磁共振成像均更清晰,两组之间并未有显著差异(图2),可见,本发明制备的β-葡聚糖偶联超顺磁纳米氧化铁(BSNPs)仍可以作为MRI肿瘤诊断的工具。生存曲线显示BSNPs组小鼠生存率显著提高(图3A)、肿瘤体积增长缓慢(图3B)、小鼠体重不受影响(图3C),26日时统一处死小鼠,剥离瘤体并称重,结果显示,BSNPs组小鼠肿瘤重量显著降低,明显低于混合液组(图3D),可见,本发明制备的β-葡聚糖偶联超顺磁纳米氧化铁(BSNPs)较之单独使用β-葡聚糖、β-葡聚糖和SPIO的混合液能显著缓解小鼠黑色素瘤。
2.3动物模型验证BSNPs对巨噬细胞极化的影响:
1)取4.3.2中步骤(7)所述肿瘤组织,使用眼科剪尽量剪取相同大小的组织块;
2)将组织块置于12孔板中,使用5mL注射器尾部研磨组织块,制备组织匀浆;
3)组织匀浆过200目滤布以除去未磨碎的组织,滤液滤至流式管中;
4)4℃,1500rpm离心5min;
5)弃上清,使用1mL ACK红细胞裂解液重悬细胞,室温静置1min;
6)加3mL PBS终止裂解,4℃,1500rpm离心5min;
7)弃上清,使用1mL PBS重悬细胞,再次过200目滤布以除去粘连的细胞团块,滤液滤至新流式管中;
8)同4.3.2步骤(1)所述进行细胞计数,调整细胞密度至1-5×106个/管;
9)4℃,1500rpm离心5min;
10)弃上清,按照说明书要求使用PBS稀释小鼠CD11b、F4/80、CD86和CD206的流式抗体至合适浓度,每管100μL,涡旋混匀后4℃避光孵育15min;
11)每管加1mL PBS,涡旋混匀;
12)4℃,1500rpm离心5min;
13)弃上清,并用200μL PBS重悬细胞,涡旋混匀后使用流式细胞仪检测;
14)检测结束后,使用Flow Jo软件分析检测巨噬细胞(CD11b+,F4/80+细胞群)上CD68(M1
型巨噬细胞表面标志)和CD206(M2型巨噬细胞表面标志)的荧光强度。
结果显示,BSNPs组肿瘤相关巨噬细胞向M1型极化增高最为显著(图4A),M2型极化基本不变(图4B),可见β-葡聚糖偶联超顺磁纳米氧化铁(BSNPs)较之单独使用β-葡聚糖、β-葡聚糖和SPIO的混合液能显著促进肿瘤相关巨噬细胞向M1型极化。
Claims (10)
1.一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒,其特征在于为表面偶联β-葡聚糖的超顺磁纳米氧化铁颗粒。
2.根据权利要求1所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒,其特征在于所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒是β-葡聚糖和超顺磁纳米氧化铁壳上的羧基在EDC的催化下耦合反应制得;其中β-葡聚糖和超顺磁纳米氧化铁的质量比为(1-3):5。
3.根据权利要求1所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒,其特征在于所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒通过以下方法制备得到:
1)取超顺磁纳米氧化铁溶于双蒸水中,加EDC,混合均匀,加β-葡聚糖,容器封口后25-28℃搅拌14-20小时,搅拌速度为600-800rpm;
2)将步骤1)所得溶液浓缩后加无水乙醇混合均匀,静置产生棕色沉淀;
3)分离出沉淀,于25-37℃静置10-20分钟以挥干剩余的乙醇;
4)用水重悬,配置需要浓度的溶液,超声处理15-30min以充分分散纳米颗粒,即得到所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒;
或者,其中的步骤2)和3)替换为以下步骤:
2)将步骤1)所得溶液使用100000kDa分子量透析袋在100倍体积的双蒸水中透析2天,期间至少更换4次透析液;
3)取透析袋中的液体冻干成粉。
4.根据权利要求3所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒,其特征在于步骤1)的反应体系中β-葡聚糖的浓度为0.2-0.6mg/mL,超顺磁纳米氧化铁的浓度为1mg/mL,EDC的浓度为1-1.5mg/mL。
5.权利要求1所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒的制备方法,其特征在于利用EDC作为催化剂催化β-葡聚糖与超顺磁纳米氧化铁壳上的羧基反应从而将β-葡聚糖偶联到超顺磁纳米氧化铁壳上;其中β-葡聚糖和超顺磁纳米氧化铁的质量比为1-3:5。
6.根据权利要求5所述的制备方法,其特征在于所述的制备方法包含以下步骤:
1)取超顺磁纳米氧化铁溶于双蒸水中,加EDC,混合均匀,加β-葡聚糖,容器封口后25-28℃搅拌14-20小时,搅拌速度为600-800rpm;
2)将步骤(1)所得溶液浓缩后加无水乙醇混合均匀,静置产生棕色沉淀;
3)分离出沉淀,于25-37℃静置10-20分钟以挥干剩余的乙醇;
4)用水重悬,配置需要浓度的溶液,超声处理15-30min以充分分散纳米颗粒,即得到所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒。
或者,其中的步骤2)和3)替换为:
2)将步骤1)所得溶液使用100000kDa分子量透析袋在100倍体积的双蒸水中透析2天,期间至少更换4次透析液;
3)取透析袋中的液体冻干成粉。
7.根据权利要求6所述的制备方法,其特征在于步骤1)的反应体系中β-葡聚糖的浓度为0.2-0.6mg/mL,超顺磁纳米氧化铁的浓度为1mg/mL,EDC的浓度为1-1.5mg/mL。
8.权利要求1-4中任一项所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒在制备抗肿瘤药物中的应用。
9.根据权利要求8所述的应用,其特征在于权利要求1-4中任一项所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒在制备具备肿瘤诊断和治疗双重功能的药物中的应用;优选在制备对黑色素瘤具有诊断和治疗双重功能的药物中的应用。
10.一种药物组合物,其特征在于包含权利要求1-4中任一项所述的β-葡聚糖偶联超顺磁纳米氧化铁颗粒和药学上允许的载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011496736.4A CN112569364A (zh) | 2020-12-17 | 2020-12-17 | 一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011496736.4A CN112569364A (zh) | 2020-12-17 | 2020-12-17 | 一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112569364A true CN112569364A (zh) | 2021-03-30 |
Family
ID=75135868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011496736.4A Pending CN112569364A (zh) | 2020-12-17 | 2020-12-17 | 一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112569364A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19917744A1 (de) * | 1999-04-20 | 2000-10-26 | Cognis Deutschland Gmbh | Dekorative kosmetische Zubereitungen |
JP2007297322A (ja) * | 2006-04-28 | 2007-11-15 | Toyobo Co Ltd | サイトカイン産生の促進方法 |
CN101843907A (zh) * | 2010-04-20 | 2010-09-29 | 上海纳米技术及应用国家工程研究中心有限公司 | SPIO@SiO2-WGA肠壁靶向造影剂的制备方法 |
CN105478087A (zh) * | 2016-01-06 | 2016-04-13 | 郑州英诺生物科技有限公司 | 一种基于涂覆葡聚糖的羧基磁珠的制备方法及其应用 |
CN111330023A (zh) * | 2020-03-23 | 2020-06-26 | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 一种磁性纳米复合材料及其制备方法与应用 |
-
2020
- 2020-12-17 CN CN202011496736.4A patent/CN112569364A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19917744A1 (de) * | 1999-04-20 | 2000-10-26 | Cognis Deutschland Gmbh | Dekorative kosmetische Zubereitungen |
JP2007297322A (ja) * | 2006-04-28 | 2007-11-15 | Toyobo Co Ltd | サイトカイン産生の促進方法 |
CN101843907A (zh) * | 2010-04-20 | 2010-09-29 | 上海纳米技术及应用国家工程研究中心有限公司 | SPIO@SiO2-WGA肠壁靶向造影剂的制备方法 |
CN105478087A (zh) * | 2016-01-06 | 2016-04-13 | 郑州英诺生物科技有限公司 | 一种基于涂覆葡聚糖的羧基磁珠的制备方法及其应用 |
CN111330023A (zh) * | 2020-03-23 | 2020-06-26 | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 一种磁性纳米复合材料及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
HIEU VU-QUANG: "Immune cell-specific delivery of beta-glucan-coated iron oxide nanoparticles for diagnosing liver metastasis by MR imaging", 《CARBOHYDRATE POLYMERS》 * |
刘琳等: "基于EDC/sulfo-NHS 的羧基化SPIO表面抗体耦联", 《南京医科大学学报》 * |
潘启超、胥彬: "《肿瘤药理学及化学治疗学》", 31 December 1989, 广东高等教育出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer | |
Zhang et al. | Milk-exosome based pH/light sensitive drug system to enhance anticancer activity against oral squamous cell carcinoma | |
He et al. | Tumor microenvironment-responsive multifunctional nanoplatform based on MnFe 2 O 4-PEG for enhanced magnetic resonance imaging-guided hypoxic cancer radiotherapy | |
CN114259477B (zh) | 一种促渗透、缓解肿瘤缺氧并能靶向肿瘤细胞的纳米递送体系及其制备方法和应用 | |
CN114558133B (zh) | 一种同时递送声敏剂和靶向抗体的超声靶向微泡及其制备方法和应用 | |
CN106880846B (zh) | 一种肿瘤靶向多功能纳米递药系统及制备方法和用途 | |
CN115252828B (zh) | 一种负载棉酚的团簇型超小四氧化三铁纳米粒及其制备和应用 | |
CN113230418A (zh) | 一种超小核壳结构铁纳米颗粒的制备方法及应用 | |
CN112569364A (zh) | 一种β-葡聚糖偶联超顺磁纳米氧化铁颗粒及其制备方法和应用 | |
CN113876964A (zh) | 一种肿瘤细胞膜载药体系及其构建方法和应用 | |
CN116251062A (zh) | 一种细菌膜-脂质体载药系统的制备方法及其应用 | |
CN115089734B (zh) | 载促吞噬肽的碳化MOFs纳米粒和制备方法和在视网膜母细胞瘤的成像和治疗中的应用 | |
CN110755379A (zh) | 一种能抗耐药肿瘤的靶向载药系统及其制备方法 | |
CN113827593B (zh) | 角鲨烯化西达本胺前药自组装纳米粒及制备方法与应用 | |
CN112870387B (zh) | 一种磁性纳米药物载体及其制备方法和应用 | |
CN116077460A (zh) | 一种负载化疗药物的灵芝多糖纳米粒 | |
CN113499452A (zh) | 一种负载金和二氧化锰纳米颗粒的聚n-乙烯基己内酰胺纳米凝胶及其制备和应用 | |
CN110368359A (zh) | 一种基于支化聚乙烯亚胺合成的杂化纳米水凝胶及其制备和应用 | |
CN112891339A (zh) | 包封青蒿素的血红素纳米囊泡、制备方法和用途 | |
CN114748424A (zh) | 一种脂质体递药体系及其制备方法和用途 | |
CN111973761A (zh) | 一种具有肿瘤诊疗功能的外泌体及其制备方法与应用 | |
CN111840324B (zh) | 应用于骨肉瘤细胞成像或治疗的Au DENPs-巨噬细胞复合物 | |
CN114010803B (zh) | 一种检测活体肿瘤微环境中Treg细胞的多功能靶向分子探针及其应用 | |
CN117462696B (zh) | 一种靶向中性粒细胞的纳米免疫药物及制备方法及应用 | |
CN115089726B (zh) | 一种肿瘤靶向诊疗探针及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210330 |
|
RJ01 | Rejection of invention patent application after publication |